FY2024 EPS Estimate for Dyne Therapeutics Lowered by Analyst

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 EPS estimates for Dyne Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($3.55) per share for the year, down from their prior estimate of ($3.06). HC Wainwright currently has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

Several other brokerages also recently issued reports on DYN. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Guggenheim boosted their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Morgan Stanley increased their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $51.40.

Dyne Therapeutics Price Performance

Shares of DYN traded up $0.95 during mid-day trading on Monday, reaching $29.34. 1,268,326 shares of the company's stock were exchanged, compared to its average volume of 1,493,931. The business's fifty day simple moving average is $32.42 and its 200-day simple moving average is $35.26. The stock has a market capitalization of $2.99 billion, a PE ratio of -8.24 and a beta of 1.10. Dyne Therapeutics has a 52-week low of $10.03 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25).

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 782 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the sale, the director now owns 15,962 shares of the company's stock, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Cox bought 32,000 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. This represents a -133.33 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 159,757 shares of company stock valued at $5,719,673. Insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DYN. Swiss National Bank grew its position in shares of Dyne Therapeutics by 41.5% in the first quarter. Swiss National Bank now owns 85,200 shares of the company's stock valued at $2,419,000 after purchasing an additional 25,000 shares during the period. Sei Investments Co. acquired a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $693,000. Russell Investments Group Ltd. lifted its holdings in shares of Dyne Therapeutics by 1.4% during the 1st quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company's stock worth $2,894,000 after acquiring an additional 1,447 shares during the period. ProShare Advisors LLC boosted its position in shares of Dyne Therapeutics by 44.6% in the first quarter. ProShare Advisors LLC now owns 16,307 shares of the company's stock worth $463,000 after acquiring an additional 5,028 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock worth $97,669,000 after acquiring an additional 1,110,629 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.